Toggle light / dark theme

The number of AI and, in particular, machine learning (ML) publications related to medical imaging has increased dramatically in recent years. A current PubMed search using the Mesh keywords “artificial intelligence” and “radiology” yielded 5,369 papers in 2021, more than five times the results found in 2011. ML models are constantly being developed to improve healthcare efficiency and outcomes, from classification to semantic segmentation, object detection, and image generation. Numerous published reports in diagnostic radiology, for example, indicate that ML models have the capability to perform as good as or even better than medical experts in specific tasks, such as anomaly detection and pathology screening.

It is thus undeniable that, when used correctly, AI can assist radiologists and drastically reduce their labor. Despite the growing interest in developing ML models for medical imaging, significant challenges can limit such models’ practical applications or even predispose them to substantial bias. Data scarcity and data imbalance are two of these challenges. On the one hand, medical imaging datasets are frequently much more minor than natural photograph datasets such as ImageNet, and pooling institutional datasets or making them public may be impossible due to patient privacy concerns. On the other hand, even the medical imaging datasets that data scientists have access to could be more balanced.

In other words, the volume of medical imaging data for patients with specific pathologies is significantly lower than for patients with common pathologies or healthy people. Using insufficiently large or imbalanced datasets to train or evaluate a machine learning model may result in systemic biases in model performance. Synthetic image generation is one of the primary strategies to combat data scarcity and data imbalance, in addition to the public release of deidentified medical imaging datasets and the endorsement of strategies such as federated learning, enabling machine learning (ML) model development on multi-institutional datasets without data sharing.

Tohid Didar and Jeff Weitz had a solution, but they also had a problem.

Didar, an associate professor of engineering and Weitz, a hematologist, professor of medicine and executive director of the Thrombosis & Atherosclerosis Research Institute, had collaborated to create a novel and highly promising material to improve the success of vascular grafts, but they needed a better way to test how well it worked.

Their revolutionary idea was an engineered non-stick surface combined with biological components that can repel all but a targeted group of cells — those that form the natural lining of the body’s veins and arteries.

Making room for optimism.


2bsirius video about:
Arthur C. Clarke formulated the following three “laws” of prediction:
1. When a distinguished but elderly scientist states that something is possible, he is almost certainly right. When he states that something is impossible, he is very probably wrong.
2. The only way of discovering the limits of the possible is to venture a little way past them into the impossible.
3. Any sufficiently advanced technology is indistinguishable from magic.
For Shermer:
http://www.scientificamerican.com/article.cfm?id=shermers-last-law.
Full text of Shermers article:

Shermer’s Last Law

For background on Arthur C. Clarke:

Today, Deep Longevity, a company will launch its new software as a service (SaaS) antiaging platform, SenoClock. The culmination of years of biogerontological research, SenoClock will host all of Deep Longevity’s patented aging clocks that may be used in clinical practice and other healthcare-adjacent industries.

Aging clocks available on the platform will allow its users to receive comprehensive and actionable pace of aging reports based on various data types, such as blood tests, psychological surveys, gut flora composition and more.

Longevity. Technology: Hospitals and clinics are mostly reactive when it comes to treatment, a practice that is partly due to infrastructure and partly due to human nature. However, as we discussed in our interview with Sir John Bell earlier this week, prevention must be the new paradigm and its one that better serves individuals, healthcare systems and populations as a whole. Deep Longevity’s new product SenoClock unlocks a preventive, longevity-focused mode of healthcare; a new SaaS platform, SenoClock offers physicians a single portal in which to track the aging rate of their patients, enabling them to generate personalised health plans.